{"count": 8188, "results": [{"_id": "36619226", "pmid": 36619226, "pmcid": "PMC9812811", "title": "A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes", "journal": "Int J Med Sci", "authors": ["Damanhouri ZA", "Alkreathy HM", "Alharbi FA", "Abualhamail H", "Ahmad MS"], "date": "2023-01-01T00:00:00Z", "doi": "10.7150/ijms.77206", "meta_date_publication": "2023", "meta_volume": "20", "meta_issue": "1", "meta_pages": "142-150", "score": 50276.06, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is the most often prescribed drug for people with @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ (@<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@T2D@@@). ", "citations": {"NLM": "Damanhouri ZA, Alkreathy HM, Alharbi FA, Abualhamail H, Ahmad MS. A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes Int J Med Sci. 2023;20(1):142-150. PMID: 36619226", "BibTeX": "@article{36619226, title={A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes}, author={Damanhouri ZA and Alkreathy HM and Alharbi FA and Abualhamail H and Ahmad MS}, journal={Int J Med Sci}, volume={20}, number={1}, pages={142-150}}"}}, {"_id": "34904090", "pmid": 34904090, "pmcid": "PMC8638058", "title": "Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data", "journal": "World J Clin Cases", "authors": ["Min HK", "Kim SH", "Choi JH", "Choi K", "Kim HR", "Lee SH"], "date": "2021-11-26T00:00:00Z", "doi": "10.12998/wjcc.v9.i33.10198", "meta_date_publication": "2021 Nov 26", "meta_volume": "9", "meta_issue": "33", "meta_pages": "10198-10207", "score": 50273.945, "text_hl": "@SPECIES_9606 @@@Patients@@@ with @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@T2DM@@@ and no complications were divided into statin/@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@/statin + @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ users and non-users. ", "citations": {"NLM": "Min HK, Kim SH, Choi JH, Choi K, Kim HR, Lee SH. Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data World J Clin Cases. 2021 Nov 26;9(33):10198-10207. PMID: 34904090", "BibTeX": "@article{34904090, title={Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data}, author={Min HK and Kim SH and Choi JH and Choi K and Kim HR and Lee SH}, journal={World J Clin Cases}, volume={9}, number={33}, pages={10198-10207}}"}}, {"_id": "36145361", "pmid": 36145361, "pmcid": "PMC9505840", "title": "Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1-4", "journal": "Pharmaceuticals (Basel)", "authors": ["Yang A", "Lau ESH", "Wu H", "Ma RCW", "Kong APS", "So WY", "Luk AOY", "Fu AWC", "Chan JCN", "Chow E"], "date": "2022-09-13T00:00:00Z", "doi": "10.3390/ph15091140", "meta_date_publication": "2022 Sep 13", "meta_volume": "15", "meta_issue": "9", "meta_pages": "", "score": 50273.688, "text_hl": "Attenuated Risk Association of End-Stage @DISEASE_Kidney_Diseases @DISEASE_MESH:D007674 @@@Kidney Disease@@@ with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@Type 2 Diabetes@@@ with eGFR Categories 1-4", "citations": {"NLM": "Yang A, Lau ESH, Wu H, Ma RCW, Kong APS, So WY, Luk AOY, Fu AWC, Chan JCN, Chow E. Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1-4 Pharmaceuticals (Basel). 2022 Sep 13;15(9):. PMID: 36145361", "BibTeX": "@article{36145361, title={Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1-4}, author={Yang A and Lau ESH and Wu H and Ma RCW and Kong APS and So WY and Luk AOY and Fu AWC and Chan JCN and Chow E}, journal={Pharmaceuticals (Basel)}, volume={15}, number={9}}"}}, {"_id": "33310173", "pmid": 33310173, "pmcid": "PMC7833191", "title": "Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study", "journal": "Diabetes Res Clin Pract", "authors": ["Jiang N", "Chen Z", "Liu L", "Yin X", "Yang H", "Tan X", "Wang J", "Li H", "Tian M", "Lu Z", "Xiong N", "Gong Y"], "date": "2021-03-01T00:00:00Z", "doi": "10.1016/j.diabres.2020.108619", "meta_date_publication": "2021 Mar", "meta_volume": "173", "meta_issue": "", "meta_pages": "108619", "score": 50272.996, "text_hl": "Characteristics of @DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@COVID-19@@@ @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ in the @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and Non-@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ groups before and after propensity score matching.", "citations": {"NLM": "Jiang N, Chen Z, Liu L, Yin X, Yang H, Tan X, Wang J, Li H, Tian M, Lu Z, Xiong N, Gong Y. Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study Diabetes Res Clin Pract. 2021 Mar;173():108619. PMID: 33310173", "BibTeX": "@article{33310173, title={Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study}, author={Jiang N and Chen Z and Liu L and Yin X and Yang H and Tan X and Wang J and Li H and Tian M and Lu Z and Xiong N and Gong Y}, journal={Diabetes Res Clin Pract}, volume={173}, pages={108619}}"}}, {"_id": "36355535", "pmid": 36355535, "pmcid": "PMC9699540", "title": "Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19", "journal": "Pharmaceuticals (Basel)", "authors": ["Al-Kuraishy HM", "Al-Gareeb AI", "Albogami SM", "Jean-Marc S", "Nadwa EH", "Hafiz AA", "A Negm W", "Kamal M", "Al-Jouboury M", "Elekhnawy E", "Batiha GE", "Waard M"], "date": "2022-11-07T00:00:00Z", "doi": "10.3390/ph15111361", "meta_date_publication": "2022 Nov 7", "meta_volume": "15", "meta_issue": "11", "meta_pages": "", "score": 50272.824, "text_hl": "@<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@T2DM@@@ @SPECIES_9606 @@@patients@@@ are commonly treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ monotherapy or @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ plus @CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitagliptin@@@. ", "citations": {"NLM": "Al-Kuraishy HM, Al-Gareeb AI, Albogami SM, Jean-Marc S, Nadwa EH, Hafiz AA, A Negm W, Kamal M, Al-Jouboury M, Elekhnawy E, Batiha GE, Waard M. Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19 Pharmaceuticals (Basel). 2022 Nov 7;15(11):. PMID: 36355535", "BibTeX": "@article{36355535, title={Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19}, author={Al-Kuraishy HM and Al-Gareeb AI and Albogami SM and Jean-Marc S and Nadwa EH and Hafiz AA and A Negm W and Kamal M and Al-Jouboury M and Elekhnawy E and Batiha GE and Waard M}, journal={Pharmaceuticals (Basel)}, volume={15}, number={11}}"}}, {"_id": "33442187", "pmid": 33442187, "pmcid": "PMC7784158", "title": "Prevalence of Vitamin B12 Deficiency and its Associated Factors among Patients with Type 2 Diabetes Mellitus on Metformin from a District in Malaysia", "journal": "J ASEAN Fed Endocr Soc", "authors": ["Krishnan GD", "Zakaria MH", "Yahaya N"], "date": "2020-01-01T00:00:00Z", "doi": "10.15605/jafes.035.02.03", "meta_date_publication": "2020", "meta_volume": "35", "meta_issue": "2", "meta_pages": "163-168", "score": 50272.41, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is widely recommended as a first line agent in the treatment of @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@type 2 DM@@@. ", "citations": {"NLM": "Krishnan GD, Zakaria MH, Yahaya N. Prevalence of Vitamin B12 Deficiency and its Associated Factors among Patients with Type 2 Diabetes Mellitus on Metformin from a District in Malaysia J ASEAN Fed Endocr Soc. 2020;35(2):163-168. PMID: 33442187", "BibTeX": "@article{33442187, title={Prevalence of Vitamin B12 Deficiency and its Associated Factors among Patients with Type 2 Diabetes Mellitus on Metformin from a District in Malaysia}, author={Krishnan GD and Zakaria MH and Yahaya N}, journal={J ASEAN Fed Endocr Soc}, volume={35}, number={2}, pages={163-168}}"}}, {"_id": "36407271", "pmid": 36407271, "pmcid": "PMC9669516", "title": "Metformin Reduces the Incidence of Sensorineural Hearing Loss in Patients With Type 2 Diabetes Mellitus: A Retrospective Chart Review", "journal": "Cureus", "authors": ["Miwa T", "Kita T", "Yamaguchi T", "Sakamoto T"], "date": "2022-10-17T00:00:00Z", "doi": "10.7759/cureus.30406", "meta_date_publication": "2022 Oct", "meta_volume": "14", "meta_issue": "10", "meta_pages": "e30406", "score": 50272.285, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is commonly used to treat @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@T2DM@@@. ", "citations": {"NLM": "Miwa T, Kita T, Yamaguchi T, Sakamoto T. Metformin Reduces the Incidence of Sensorineural Hearing Loss in Patients With Type 2 Diabetes Mellitus: A Retrospective Chart Review Cureus. 2022 Oct;14(10):e30406. PMID: 36407271", "BibTeX": "@article{36407271, title={Metformin Reduces the Incidence of Sensorineural Hearing Loss in Patients With Type 2 Diabetes Mellitus: A Retrospective Chart Review}, author={Miwa T and Kita T and Yamaguchi T and Sakamoto T}, journal={Cureus}, volume={14}, number={10}, pages={e30406}}"}}, {"_id": "33668426", "pmid": 33668426, "pmcid": "PMC7918864", "title": "Therapeutic Applications of Type 2 Diabetes Mellitus Drug Metformin in Patients with Osteoarthritis", "journal": "Pharmaceuticals (Basel)", "authors": ["Song P", "Hwang JS", "Park HC", "Kim KK", "Son HJ", "Kim YJ", "Lee KM"], "date": "2021-02-13T00:00:00Z", "doi": "10.3390/ph14020152", "meta_date_publication": "2021 Feb 13", "meta_volume": "14", "meta_issue": "2", "meta_pages": "", "score": 50271.848, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is the first-line mediation treatment for @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@T2DM@@@. ", "citations": {"NLM": "Song P, Hwang JS, Park HC, Kim KK, Son HJ, Kim YJ, Lee KM. Therapeutic Applications of Type 2 Diabetes Mellitus Drug Metformin in Patients with Osteoarthritis Pharmaceuticals (Basel). 2021 Feb 13;14(2):. PMID: 33668426", "BibTeX": "@article{33668426, title={Therapeutic Applications of Type 2 Diabetes Mellitus Drug Metformin in Patients with Osteoarthritis}, author={Song P and Hwang JS and Park HC and Kim KK and Son HJ and Kim YJ and Lee KM}, journal={Pharmaceuticals (Basel)}, volume={14}, number={2}}"}}, {"_id": "32377525", "pmid": 32377525, "pmcid": "PMC7189314", "title": "Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study", "journal": "J Diabetes Res", "authors": ["Fan YP", "Wu CT", "Lin JL", "Hsiung CA", "Liu HY", "Lai JN", "Yang CC"], "date": "2020-04-19T00:00:00Z", "doi": "10.1155/2020/9161039", "meta_date_publication": "2020", "meta_volume": "2020", "meta_issue": "", "meta_pages": "9161039", "score": 50271.746, "text_hl": "These results may recommend @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for early treatment of @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@T2DM@@@.", "citations": {"NLM": "Fan YP, Wu CT, Lin JL, Hsiung CA, Liu HY, Lai JN, Yang CC. Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study J Diabetes Res. 2020;2020():9161039. PMID: 32377525", "BibTeX": "@article{32377525, title={Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study}, author={Fan YP and Wu CT and Lin JL and Hsiung CA and Liu HY and Lai JN and Yang CC}, journal={J Diabetes Res}, volume={2020}, pages={9161039}}"}}, {"_id": "33664666", "pmid": 33664666, "pmcid": "PMC7921791", "title": "Obesity Connected Metabolic Changes in Type 2 Diabetic Patients Treated With Metformin", "journal": "Front Pharmacol", "authors": ["Aleidi SM", "Dahabiyeh LA", "Gu X", "Al Dubayee M", "Alshahrani A", "Benabdelkamel H", "Mujammami M", "Li L", "Aljada A", "Abdel Rahman AM"], "date": "2021-02-16T00:00:00Z", "doi": "10.3389/fphar.2020.616157", "meta_date_publication": "2020", "meta_volume": "11", "meta_issue": "", "meta_pages": "616157", "score": 50271.504, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is widely used in the treatment of @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@Type 2 Diabetes Mellitus@@@ (@<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@T2DM@@@). ", "citations": {"NLM": "Aleidi SM, Dahabiyeh LA, Gu X, Al Dubayee M, Alshahrani A, Benabdelkamel H, Mujammami M, Li L, Aljada A, Abdel Rahman AM. Obesity Connected Metabolic Changes in Type 2 Diabetic Patients Treated With Metformin Front Pharmacol. 2020;11():616157. PMID: 33664666", "BibTeX": "@article{33664666, title={Obesity Connected Metabolic Changes in Type 2 Diabetic Patients Treated With Metformin}, author={Aleidi SM and Dahabiyeh LA and Gu X and Al Dubayee M and Alshahrani A and Benabdelkamel H and Mujammami M and Li L and Aljada A and Abdel Rahman AM}, journal={Front Pharmacol}, volume={11}, pages={616157}}"}}]}